Advanced Cardiovascular Systems, Inc.

Abbott Cardiovascular Systems, Inc.

Advanced Cardiovascular Systmes, Inc.

Deborah L Kilpatrick

Jeffrey T Ellis

Robert D Ainsworth

Jeong Soo Lee

Bridget A Hurley

Murthy V Simhambhatla

Santosh V Prabhu

Syed Faiyaz Ahmed Hossainy

Paul M Consigny

Florencia Lim

Shawn Chin Quee

Florian Ludwig

Irina Astafieva

Alex Tilson

Eugene T Michal

Syed F Hossainy

Yung-Ming Chen

Yiwen Tang

Bruce M Wilson

Marc Mehrzad Jalisi

Evgenia Mandrusov

Christopher Feezor

Gordon S Stewart

Gina Zhang

Chi Le Long

Gene Park

Stephen J Bigus

Christopher J Buchko

A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo A1 comprising a hydrophobic ligand suitable to interact with cell surface binding sites. A composition including Apo A1 and an agent selected to one of increase the ATP-binding cassette protein 1 (ABCA1) transporter expression in macrophages and protect ABCA1 from thiol-mediated degradation.

Lipid therapy

An apparatus and method to treat vulnerable plaque. In one embodiment, the apparatus has a medical device to treat an occlusive plaque, and is also adapted to release a biologically active agent to treat vulnerable plaque located downstream from the occlusive plaque. In an alternative embodiment, the apparatus has an expandable tube attached to the inner surface of a stent, and a layer of endothelial cells seeded on the inner surface of the expandable tube. The expandable tube shields a vulnerable plaque from a body lumen.

Method and apparatus for treating vulnerable plaque

Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

Drug-delivery stent formulations for restenosis and vulnerable plaque

A guidewire with a sensor which can detect NO and/or superoxide levels is disclosed. This invention can be useful for in vivo analysis of vascular health.

Guidewire with chemical sensing capabilities

An apparatus and method to perform therapeutic treatment and diagnosis of a patient's vasculature through the use of an intravascular device having an optical fiber disposed therein. In an embodiment, the apparatus includes an intravascular device to perform a therapeutic treatment and at least one optical fiber disposed through the intravascular device. The optical fiber is configured to provide diagnostic information before, during, and after the therapeutic treatment. In an embodiment, diagnostic information includes vessel and blood characteristics such as hemodynamic characteristics, hematological parameters related to blood and blood components, and thermal parameters of the vasculature.

Catheter with optical fiber sensor

An intravascular stent assembly for implantation in a body lumen, such as a coronary artery, is designed to treat a lesion with vulnerable plaque by reducing the fibrous cap stresses. A polymeric sleeve having first and second ends interconnects a first metallic stent and a second metallic stent. The first end is bonded to a distal end region of the first stent and the second end to a proximal end region of the second stent. The polymeric sleeve can be loaded with a therapeutic drug or agent to further control local thrombosis and/or induce healing if the plaque fibrous cap ruptures during or after implantation. Methods of making an intravascular stent assembly for the treatment of vulnerable plaque are also provided.

Stent assembly for the treatment of vulnerable plaque

A method of treating vulnerable plaque comprising intentionally damaging or rupturing the vulnerable plaque using a wingless balloon which is inflated from a wingless unexpanded diameter to a limited expanded diameter. This process produces significant increase in ECM synthesis at the site of the damage or rupture. As a result, the method strengthens the vulnerable plaque while minimizing or avoiding damage to the surrounding wall of the body lumen or damaging a stable plaque mistakenly believed to be a vulnerable plaque. The method of the invention is particularly useful in treating a fibroatheroma type of vulnerable plaque. In one embodiment, the balloon is self-limiting such that it expands compliantly at initial inflation pressures, and above nominal pressure it expands noncompliantly. In an alternative embodiment, the balloon is inflated using a diameter-limiting device, such as a device which limits the inflation pressure or the volume of inflation fluid in the balloon.

Device for treating vulnerable plaque

Apparatus and method to perform therapeutic treatment and diagnosis of a patient's vasculature through the use of an intravascular device having an optical fiber disposed therein. In an embodiment of this invention, the apparatus includes a therapeutic guidewire and at least one optical fiber disposed through the therapeutic guidewire, the optical fiber capable of providing diagnostic information before, during, and after the therapeutic treatment. In an embodiment, diagnostic information includes vessel and blood characteristics such as hemodynamic characteristics, hematological parameters related to blood and blood components, and thermal parameters of the vasculature.

Guidewire with optical fiber

An apparatus and method to treat vulnerable plaque. In one embodiment, the apparatus has an elongated catheter body adapted for insertion in a body lumen, with a drug delivery device attached near a distal portion of the elongated body. The drug delivery device is configured to deliver a biologically active agent to stabilize a vulnerable plaque.

Method of treating vulnerable plaque

Growing community of inventors

Mountain View, CA, United States of America

Deborah L Kilpatrick